Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis

Journal of Infectious Diseases

Volumn 183, Issue 7, 2001, Pages 1079-1086

  Cross, Alan S ^a   Opal, Steven M ^c   Warren, H Shaw ^d   Palardy, John E ^c   Glaser, Kathleen ^a   Parejo, Nicolas A ^c   Bhattacharjee, Apurba K ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c BROWN UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CYCLOPHOSPHAMIDE; ENDOTOXIN; LIPOPOLYSACCHARIDE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; EXPERIMENTAL ANIMAL; FEMALE; FEVER; GRAM NEGATIVE INFECTION; IMMUNE DEFICIENCY; KLEBSIELLA PNEUMONIAE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; SURVIVAL;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CEFTAZIDIME; CEPHALOSPORINS; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; ENDOTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI VACCINES; FEMALE; KLEBSIELLA PNEUMONIAE; LIPOPOLYSACCHARIDES; NEISSERIA MENINGITIDIS; NEUTROPENIA; PSEUDOMONAS AERUGINOSA; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS; VACCINES, CONJUGATE;

EID: 0035313389     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/319297     Document Type: Article

References (30)

1. Long-term survival and function after suspected gram-negative sepsis
2. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome
3. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial
4. Treatment of gram-negative bacteremia in septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial
5. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli
6. Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis
7. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis group B outer membrane protein produces protective antibodies against gram-negative bacteremia
8. Oral ciprofloxacin and anti-lipopolysaccharide monoclonal antibody protect leukopenic rats from lethal infection
9. β-lactam antibiotic-induced release of free endotoxin: In vivo comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP-specific ceftazidime
10. Treatment of gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial
11. Preliminary study on treatment of septic shock patients with antilipopolysaccharide IgG from blood donors
12. Prevention of gramnegative shock and death in surgical patients by antibody to endotoxin core glycolipid
13. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial
14. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection
15. Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: A prospective double-blind study
16. Antibodies to lipopolysaccharide after immunization of humans with the rough mutant Escherichia coli
17. Human vaccination with Escherichia coli J5 mutant induces cross-reactive bactericidal antibody against Neisseria gonorrhoeae lipopooligosaccharide
18. Immunization with rough mutants of Salmonella minnesota: Initial studies in human subjects
19. Characterization of the human antibody response to an Escherichia coli O111:B4 (J5) vaccine
20. Immunotherapy with antibodies to core lipopolysaccharide: A critical appraisal
21. New trends in Escherichia coli O111:B4 J5 mutant (Rc chemotype) vaccine development for use in gram-negative bacillary sepsis
22. Cross-reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other gram-negative bacteria
23. Immunotherapy of gram-negative bacterial sepsis: Enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5
24. Treatment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-GAL epimerase-deficient mutant
25. Antibody to cell wall glycolipid of gram-negative bacteria: Induction to immunity to bacteremia and endotoxemia
26. Bacteremia and severe sepsis in adults: A multicenter prospective survey in ICUs and wards of 24 hospitals
27. The prevalence of nosocomial infection in intensive care units in Europe
28. The natural history of the systemic inflammatory response syndrome (SIRS)
29. Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an 8-valent Pseudomonas O-polysaccharide conjugate vaccine administered to acute trauma victims
30. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis